LATEST
GTCR agreed to acquire CCC Intelligent SolutionsEQT agreed to acquire StockbridgeProofpoint agreed to acquire VaronisPyrophyte Acquisition . II / SakuuMotown Acquisition agreed to acquire Penske Automotive GroupVivos Therapeutics / SOD SciencesAtlasClear Holdings agreed to acquire Ark Financial ServicesLaboratory of America Holdings / BioReference HealthMubadala Capital acquired Clear Channel OutdoorIthaca Holdings agreed to acquire BumblePenta Fine Ingredients acquired SynerzineHexagon agreed to acquire Rocscience
Open App
ClosedPublished 2 Mar 2026

Eton Pharmaceuticals, Inc. /
Pierre Fabre Medicament Sas

Eton Pharmaceuticals, Inc. takes U.S. rights to HEMANGEOL from Pierre Fabre Medicament Sas

Buy side: Eton Pharmaceuticals, Inc.
Buy sideEton Pharmaceuticals, Inc.
Target: Pierre Fabre Medicament Sas
TargetPierre Fabre Medicament Sas
Eton Pharmaceuticals, Inc. · 2 Mar 2026Source
See the source
Buy side: Eton Pharmaceuticals, Inc.
Buy sideEton Pharmaceuticals, Inc.
Target: Pierre Fabre Medicament Sas
TargetPierre Fabre Medicament Sas
01 / BuyerEton Pharmaceuticals, Inc.
02 / TargetPierre Fabre Medicament Sas
Source for the buyer and target: Eton Pharmaceuticals, Inc.

For the buyer and target.

“On February 27, 2026, Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) entered into a licensing agreement and acquired the U.S. rights to HEMANGEOL® (propranolol) oral solution from Pierre Fabre Medicament Sas (“Licensor”).”

Published 2 Mar 2026

Open the source
01

What happened

Eton Pharmaceuticals, Inc. acquired the U.S. rights to HEMANGEOL® (propranolol) oral solution from Pierre Fabre Medicament Sas on Feb. 27, 2026, through a licensing agreement. HEMANGEOL is an Orphan Drug for proliferating infantile hemangioma that requires systemic therapy. [01]

Eton will pay $14.0 million upfront plus an 8% royalty on net sales for the life of the product's patent protection. It will also buy about $1.5 million of inventory at closing and an estimated $0.7 million more in May 2026. Cash on hand financed the deal. [01]

Pierre Fabre will keep selling the product in the U.S. until April 30. Eton takes over U.S. commercialization on May 1. [01]

02

The source

Everything on this page comes from the source below, quoted word for word.

01
Source · Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. takes U.S. rights to HEMANGEOL from Pierre Fabre Medicament Sas

This document is the source for the companies, stage, figure and people on this page.

Open the source
03

Timeline

Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.

  1. Closed

    “Eton Pharmaceuticals, Inc. takes U.S. rights to HEMANGEOL from Pierre Fabre Medicament Sas Eton Pharmaceuticals, Inc. acquired the U.S. rights to HEMANGEOL® (propranolol) oral solution from Pierre Fabre Medicament Sas…”

    Open the source

  2. Published by Eton Pharmaceuticals, Inc.

    The source this page is built from.

    Open the source

  3. Deadline

    “Pierre Fabre will keep selling the product in the U.S. until April 30”

    Open the source

  4. Also stated

    “It will also buy about $1.5 million of inventory at closing and an estimated $0.7 million more in May 2026”

    Open the source

  5. Also stated

    “Eton takes over U.S. commercialization on May 1”

    Open the source

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Get ProAlready a member? Sign in

Pro is open to everyone.